Tamir Grunberg

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Valvular heart disease is currently treated with mechanical valves, which benefit from longevity, but are burdened by chronic anticoagulation therapy, or with bioprosthetic valves, which have reduced thromboembolic risk, but limited durability. Tissue engineered heart valves have been proposed to resolve these issues by implanting a scaffold that is(More)
  • 1